Four thousand, four hundred and forty eligible children of up to 18 years of age were treated in four consecutive trials between 1981 and 1995 with the treatment protocols of the Berlin-Frankfurt-Mü nster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). The probability for eventfree survival (pEFS) at 8 years improved from 65.8% in study ALL-BFM 81 to 75.9% in study ALL-BFM 90. The cumulative incidence of recurrences with CNS involvement was 10.1% and 9.3% in studies ALL-BFM 81 and 83, but was reduced to less than 5% in study ALL-BFM 90 (for isolated CNS relapses from 5.3% in study ALL-BFM 81 to 1.1% in study ALL-BFM 90). Four major findings were derived from this series of trials performed by 37 to 96 centers in Germany, Austria, and Switzerland: (1) Reintensification is a crucial part of treatment, even in low risk patients; (2) presymptomatic cranial radiotherapy can be safely reduced to 12 Gy, or even be eliminated if it is replaced by early intensive systemic and intrathecal methotrexate applied; (3) maintenance therapy given a total of 24 months from diagnosis provides a lower rate of systemic relapses than treatment for 18 months; (4) inadequate response to an initial 7-day prednisone window (combined with one intrathecal injection of methotrexate on day 1) defines about 10% of the patients with a very high risk of relapse. For patients with adequate early response (90% of all) an 8-year pEFS of 80% has been achieved in the most recent trial ALL-BFM 90. While it has proven so far to be impossible to improve the outcome for the small group of high risk patients, the number of recurrences could be effectively reduced for the large group of patients responding adequately to the prednisone in vivo sensitivity test. Apart from inadequate prednisone response, patients with hyperleukocytosis, age Ͻ1 year, or the presence of the Philadelphia-chromosome (Ph + ALL) are at a particularly high risk of failure. Leukemia (2000) 14, 2205-2222.
Introduction
The results from research on drug resistance and the first clinical long-term remissions by the use of drug combinations and central nervous system irradiation 1 initiated the first clinical trial with a new intensive multiagent approach known as the 'West-Berlin pilot study' performed from 1970 to 1976. 2 This treatment used an 8-agent, 8-week induction (protocol I) which was combined in its second phase with preventive cranial irradiation. The probability of event-free survival at 5 years was 55% (±6%). It was, however, evident that patients with high white blood cell count could not be treated adequately by this approach and needed a reinforced intensification. 3 Patients with thymic involvement could be treated quite successfully with this therapy. 4 The introduction of reintensification with protocol II (which was basically a repetition of the induction element) for all high risk patients in study BFM 76/79 improved the outcome for high risk patients significantly. 5, 6 In April 1981, 37 centers from Germany started the fourth Berlin-Frankfurt-Mü nster (BFM) trial (ALL-BFM 81) in which a new system of risk stratification was used, the BFM risk factor (RF) which is a measurement of the cell mass at diagnosis. 7 Two randomized questions focused on ways to reduce the treatment morbidity: (1) In standard risk patients in which the BFM RF was below 1.2 (by that definition including 60% of all patients), the efficacy of preventive cranial radiotherapy was compared to that of intravenous (i.v.) intermediate-dose methotrexate (IDM MTX, 0.5 g/m 2 /24 h × 4) combined with intrathecal (IT) MTX; (2) shortened maintenance treatment: 18 months of treatment was compared to 24 months. 8 Overall improvement was sought by increasing the single anthracycline dose from 25 to 30 mg/m 2 , and in high-risk patients by introducing an extended version of reintensification. Vincristine/prednisone pulses which had shown minimal benefit in previous trials, were no longer used in maintenance therapy. 9 In October 1983, the next study (ALL-BFM 83) was initiated in 46 centers. Treatment was stratified by BFM risk factor, and the randomized questions focused again on reduction of treatment intensity in standard risk patients: (1) Could the 4-week reintensification element (protocol III) be omitted in low-standard risk patients (RF Ͻ0.8)? (2) Is 12 Gy of preventive CRT as effective as 18 Gy in high-standard risk patients (RF 0.8-Ͻ1.2)? (3) Could the treatment duration be shortened from 24 to 18 months? In high risk patients (RF у1.7), early intensification of treatment given before regular induction therapy was tested for improvement of outcome in that small but poor prognosis subset. In a concerted effort to identify new prognostic factors correlating with intrinsic drug resistance, a 7-day prednisone prephase was introduced for all patients. 10 The reduction of leukemic blasts in peripheral blood was centrally evaluated. The practical purpose was the reduction of morbidity derived from tumor lysis by a prephase scheme in which a slow dose increase of prednisone was permitted in patients with high WBC.
In trial ALL-BFM 86 which began in October 1986 with 61 centers from Germany and Austria, the stratification system used since 1981 was extended by the use of the early in vivo response to the 7-day prednisone prephase which had been found in the previous study to be of strong prognostic significance. A leukemic blast cell count in peripheral blood (PB) of 1000 per l or more on day 8 (prednisone poor response, PPR) characterized a group of patients who developed very early relapses. 10, 11 The final outcome of the PPR group was nearly half as good as that of patients who had less than 1000 blasts in PB after the prednisone prephase (prednisone good Leukemia response, PGR). In an attempt to further reduce CRT, highdose methotrexate was introduced in all patients during consolidation therapy (protocol M). For overall disease control, the dose of anthracyclines and the dose intensity in induction was increased. For high risk patients, now mainly identified by prednisone poor response, an experimental, intensive consolidation treatment was initiated (protocol E). In particular, outcome of patients with T cell ALL clearly improved compared to the previous trial ALL-BFM 83, most likely due to the use of high-dose methotrexate. This strategy for T cell disease was also used successfully for lymphoblastic T cell nonHodgkin lymphoma (T-LB-NHL). 12 In trial ALL-BFM 90 with 96 participating centers, treatment modifications aimed for a reduction of long-term morbidity in the large group of patients with prednisone good response (standard and medium risk) by limiting CRT to medium and high risk patients with a dose of 12 Gy, and by using less anthracyclines in induction. 13 On the other hand, a further improvement in outcome was attempted by higher dose intensity in induction (by combining more drugs in a shorter period of time), by additional use of L-asparaginase in consolidation (randomization in medium risk patients), by more early intrathecal CNS-directed therapy, and by treatment of high risk patients after induction with short rotating pulses of intensive chemotherapy derived from the BFM relapse strategy.
14 In high-risk patients, treatment-related morbidity was investigated in a randomized phase III study of r-metHuG-CSF. 15 Identification of patients with translocation t(9;22)(q34;q11) was improved by molecular screening for BCR/ABL. 16 Long-term follow-up of clinical trials is an important element of responsible clinical research, in particular in diseases such as childhood leukemia which require cytotoxic therapy with potentially severe acute and delayed adverse side-effects. A number of prognostic factors has been described for ALL for which the significance depends on the availability of diagnostic tools (eg minimal residual disease is only relevant if it can be measured) as much as on the quality of treatment. For comparison of treatment results, common evaluation criteria are an essential prerequisite. Contemporary risk classification systems such as the Rome Workshop Recommendations or the NCI risk criteria which are used for this analysis of long-term follow-up results are a useful basis for such comparisons even though they do not include response evaluation for risk group definition.
17,18

Materials and methods
Patients
From 1 April 1981 until 31 March 1995, 4699 patients of up to 18 years of age were enrolled in participating centers in Germany, Austria, and Switzerland. Twenty-two, 35, 80, and 122 patients (in total 5.5%) were not eligible in trials ALL-BFM 81, 83, 86, and 90, respectively, according to protocol criteria: significant pretreatment (steroids or cytostatic drugs given within 4 weeks prior to diagnosis); pilot patients for subsequent trials; patients treated with a different protocol; diagnosis and/or treatment was performed outside the participating countries; diagnosis of ALL could not be reliably established; a major additional medical ailment prevented protocol therapy (patients with Down's syndrome were only excluded if combined with severe congenital heart defect); essential data missing to calculate the BFM risk factor (BFM-RF); ALL was a second malignancy, or relapse of previously not recognized ALL. Thus, 4440 patients were eligible and evaluable for this study: 611 patients in study ALL-BFM 81, 653 in study ALL-BFM 83, 998 patients in study ALL-BFM 86, and 2178 patients in study ALL-BFM 90 (Table 1) . For each patient, informed consent was obtained from the parents or guardians.
The follow-up monitoring was performed by sending out questionnaires to participating centers on a yearly or bi-yearly basis. For patients having reached an age of Ͼ18 years, longterm follow-up since 1998 is organized by the German Childhood Cancer Registry (Institute for Medical Statistics, University of Mainz, Germany). Of all 4440 patients, 406 patients are considered lost-to-follow-up (LFU). Of 159 such patients in trial ALL-BFM 81, 124 had a follow-up (FU) in CR of у5 years. The corresponding patient numbers in trial ALL-BFM 83 are 90 patients (50 patients у5 years FU in CR), 99 patients (53 patients у5 years FU in CR) in trial ALL-BFM 86, and 58 patients (17 patients у5 years FU in CR) in trial ALL-BFM 90.
Diagnosis
The diagnosis was (centrally) established by morphological FAB criteria and cytochemistry when at least 25% lymphoblasts were present in the bone marrow (BM), or when blasts were present in the PB. 19 CNS involvement was diagnosed if Ͼ5 cells per l were counted in the CSF, and if lymphoblasts were identified unequivocally, or if intracerebral infiltrates were detected on cranial computed tomography. 20 Immunophenotyping was performed as described elsewhere. 21, 22 Surface antigens were considered positive if у20% of the leukemic cells expressed the antigen with more than 98% fluorescence intensity as compared to negative control cells. For TdT and cytoplasmic (cy) antigens, positivity was defined as more than 10% of the cells exhibiting nuclear or intracytoplasmatic fluorescence (TdT, cyIgM, cyCD3). Since 1994, two-color flow cytometric analysis was introduced using appropriate monoclonal antibodies directly conjugated to fluorescein isothiocyanate or phycoerythrin. Immunophenotypic subgroups were defined according to the EGIL definition as follows: Pro-B ALL: TdT + . 23 Co-expression of myeloid antigen(s) was defined as simultaneous expression of one or more of the myeloid lineage-associated molecules tested (CD13, CD33, CD65s) on at least 20% of the lymphoblasts. Cytogenetic studies were carried out using standard techniques as described elsewhere. 24 Since November 1992, RT-PCR-based screening for BCR/ABL was offered to participating centers. 16 Cellular DNA content was determined using flow cytometry as previously described. 25 The DNA index (DI) of the leukemic blasts was defined as the ratio of DNA content in leukemic G0/G1 cells to that of normal diploid lymphocytes. A cut-off for DI at 1.16 was used to distinguish prognostic categories.
Estimation of the leukemic cell mass at diagnosis (BFM risk factor: RF)
The leukemic cell mass was calculated by the equation: RF = 0.2 × log (number of blood blasts/l + 1) + 0.06 × liver size + 0.04 × spleen size (organ size in cm below the costal margin). 
Definition of prednisone response
Since trial ALL-BFM 83, therapy for all patients started with a 7-day monotherapy with prednisone and one intrathecal dose of methotrexate (IT MTX) on day 1. The first day of treatment is the day of the first administration of prednisone. The dosage of prednisone is increased steadily to 60 mg/m 2 daily according to leukemic cell mass, renal, and metabolic parameters in order to circumvent complications of acute cell lysis. From the absolute leukocyte count and the percentage of blasts in PB smears the number of leukemic blasts in the blood on day 8 can be calculated (performed by central review in the study center). The presence of у1000/l blasts in the blood on day 8 is defined as prednisone poor response (PPR); a count of leukemic cells in blood of Ͻ1000/l is required for the diagnosis of prednisone good response (PGR). 10 
Risk group definitions
In Figure 1 , the risk groups are presented with the treatment outline. In study ALL-BFM 81, the risk groups were defined by the BFM risk factor (RF) into three risk groups: standard risk comprised 60% of all patients, and was defined by a BFM-RF of Ͻ1.2, medium risk (30% of all patients) was defined by a RF of 1.2-Ͻ1.7, and high risk (10% of all) by a RF of у1.7. In study ALL-BFM 83, the standard risk group was subdivided into low-standard (RF Ͻ0.8 and no CNS disease) and highstandard risk group (RF 0.8-Ͻ1.2), both comprising approximately 30% of all patients. Medium and high risk patients were defined as in study ALL-BFM 81.
Leukemia
Since study ALL-BFM 86, stratification was based upon the BFM-RF and the early response to prednisone: standard risk patients (approximately 30% of the total group) were defined by the combination of RF Ͻ0.8, PGR, no CNS involvement, and no mediastinal tumor. Medium risk patients (RG in study 86, MRG in study 90) were defined either by an increased RF (у0.8) and PGR, or by PGR and/or CNS involvement or mediastinal tumor, independently of the BFM-RF. High risk patients (experimental group, EG, in study 86; HRG in study 90) were defined by PPR, or by non-response to induction phase I/A (day 40). In study ALL-BFM 90, patients were basically stratified as in study 86 except that T-ALL (instead of mediastinal tumor) excluded standard risk, and Ph+ ALL was an additional criterion for high risk (HR).
Treatment
The treatment of the four trials is schematically shown in Figure 1 , with some details provided in the legend. Details regarding dosage and exact timing are published elsewhere. 8, 10, 11, 13 The major study questions addressed in each trial were summarized in the Introduction of this article. Despite a common 'backbone' in all four trials derived from the previous BFM concept, 3, 6, 26 some modifications should be pointed out.
Anthracyclines:
In as Prot II but also with VM-26 and additional ARA-C. Block 1/2/3 in HR-90: intensive short pulses followed by (R = randomized) prophylactic G-CSF. 13, 15 Maintenance therapy: see text for details. Dosage of presymptomatic cranial irradiation (CRT) as indicated. *Protocol amendment 1.5 years after start of study ALL-BFM 86: reintensification (Protocol II) was introduced for SRG, and maintenance treatment for all risk groups was extended to 24 months (from 18 months).
11 Details of 'Protocol E' and the role of late intensification randomized in a subgroup of intermediate risk patients of study ALL-BFM 86 have been published.
11 PGR (PPR): prednisone good (poor) response; med mass: mediastinal mass; RF: BFM risk factor (see: Materials and methods).
cation, the dose of adriamycin was also increased to 30 mg/m 2 × 4 vs 25 mg × 4 as before. 26 In trial ALL-BFM 86, the dose was further increased to 40 mg/m 2 × 4 in induction, 11 but subsequently decreased again to 30 mg/m 2 × 4 in trial ALL-BFM 90. 13 Thus, cumulative dose since trial ALL-BFM 81 has been 240 mg/m 2 for most patients (180 mg for standardrisk patients receiving only protocol III as reintensification), except in trial ALL-BFM 86 in which cumulative anthracycline dose was 280 mg/m 2 .
L-asparaginase:
L-asparaginase (ASP; E. coli preparation from Bayer, Leverkusen, Germany) was applied daily in induction at 5000 U/m 2 /day i.v. (days 1-21), but in the subsequent trials ALL-BFM 83, 86, and 90 L-ASP was used every 3 days with 10 000 U/m 2 i.v., starting day 26 (study 83), day 19 (study 86), and day 12 (study 90) of induction. In reintensification (protocol II or III), ASP has always been used at 10 000 U/m 2 /day i.v. twice weekly for weeks 1 and 2. 8 In all trials, Erwinia asparaginase was usually used as replacement if allergic reactions occurred due to the use of E. coli asparaginase. Since study ALL-BFM 90, E. coli asparaginase (from Medac, Hamburg, Germany) has mainly been used. 13 
Methotrexate:
Intermediate dose i.v. methotrexate (0.5 g/m 2 × 4, 24 h infusion) was introduced as part of the extracompartment therapy (now called 'consolidation'; Figure 1 ) in study ALL-BFM 81 for the randomized study in standard risk patients. In study ALL-BFM 83 it was used in all strata, but replaced by high-dose methotrexate (HD-MTX; 5.0 g/m 2 × 4) in study ALL-BFM 86 and 90. Except in high-risk patients of study ALL-BFM 90, HD-MTX has always been used in conjunction with IT MTX. 11 HR patients of study ALL-BFM 90 received HD-MTX within the pulses HR-1 and 2 combined with MTX, ARA-C, and prednisone (PRED) given intrathecally, and other systemically applied drugs. 13 
Prednisone/dexamethasone:
In induction, prednisone has been applied with a daily dose of 2.5 mg/kg or 60 mg/m 2 for 28 days (followed by a tapering down phase) since trial ALL-BFM 70. 3, 8, 26 Beginning with trial ALL-BFM 83, induction therapy was started with a 1-week prednisone window to evaluate the in vivo response. To avoid morbidity from cell lysis, a stepwise increase to full dose was allowed.
10 Dexamethasone (DEXA) has been used in reintensification for 2 weeks (plus tapering down) in protocol III at 10 mg/m 2 /day (in BFM trials 70-79 with 15 mg/m 2 /day), for 4 weeks (plus tapering down) in protocol II of studies ALL-BFM 81 and 83, and for 3 weeks in protocol II in studies ALL-BFM 86 and 90. 8, 11, 13, 27 Reintensification:
Three different treatment elements have been used for delayed reintensification (Figure 1 ): protocols II, III and IV. Protocol III was a 4-week course, protocol II was a 6-week (studies 81 and 83) or 7-week course in studies ALL-BFM 86 and 90, containing more DEXA (see above), anthracyclines and vincristine (four instead of two doses, each) than protocol III, and protocol IV was an 8-week course in which ARA-C and VP-16 had been added upfront to the regular protocol II; this element was only used in high-risk patients of study ALL-BFM 81.
Cranial radiotherapy:
Before i.v. MTX had been introLeukemia duced, presymptomatic cranial radiotherapy (CRT) was applied during the second phase of induction (protocol I, phase B). Since study ALL-BFM 83, CRT was given at the end of reintensification (Figure 1 ). In that study, the protective effect of 12 Gy as compared to 18 Gy CRT for high standardrisk patients was randomly analyzed. Doses for CRT have been reduced since study ALL-BFM 81, and radiotherapy was first eliminated for low-standard risk patients of study ALL-BFM 83. Study ALL-BFM 90 used only 12 Gy for CRT in all non-SR patients. SR patients did not receive CRT.
Intrathecal treatment:
IT MTX was applied seven times in study ALL-BFM 81, eight times in study ALL-BFM 83, nine times in study ALL-BFM 86, and 11 times in study ALL-BFM 90 (in HR patients three doses of IT MTX, and nine doses of MTX/ARA-C/PRED IT were applied). CNS-positive patients received two additional doses of IT MTX in induction and reintensification, and 24 Gy of CRT.
Duration of treatment elements:
As shown in Figure 1 , duration of induction (protocol I) varied between 8 weeks in study 81, 11 in study 83, 10 in study 86, and 9 weeks in study 90. In the four studies reported here, maintenance therapy was only based on MTX (orally, 20 mg/m 2 once a week), and 6-MP (orally, 50 mg/m 2 /day). Intrathecal treatment or vincristine/steroid pulses were not used in maintenance therapy. Total duration of treatment was investigated by randomization in studies ALL-BFM 81 and 83. When the advantage of 24 months total treatment duration was evident, treatment duration in the subsequent study ALL-BFM 86 was extended to 24 months.
Statistical analysis
The duration of event-free survival (EFS) is defined as the time from diagnosis until the date of an adverse event (relapse, death or the development of a second malignancy), or if no such event occurred, until the date of last contact. Patients who did not attain a complete remission were considered failures at time zero. Duration of disease-free survival (DFS; also called 'duration of continuous complete remission', CCR) for patients who achieve remission is defined as the time from attainment of a complete remission until the date of an adverse event (relapse, death, or the development of a second malignancy) or if no such event occurred, until the date of last contact. Distributions of EFS and CCR were estimated by the method of Kaplan and Meier with standard errors according to Greenwood, and were compared using the log-rank test.
28, 29 All analyses were performed on the basis of 'intentto-treat'. Cumulative incidence functions of CNS relapse were constructed by the method of Kalbfleisch and Prentice 30 for patients who achieved a complete remission. Incidence functions for all competing factors of failure were also calculated (Table 1) . Functions were compared with Gray's test. 31 A CNS relapse is defined as an isolated CNS relapse or a CNS relapse in combination with another type of relapse or failure. In the figures, the cumulative incidence (CI) of CNS relapses always comprises all recurrences with CNS involvement. The database for all analyses was 'frozen' on 1 June 2000.
Results
Results are first presented by trial and common criteria, which includes the outcome according to the NCI risk classification which is applied here to both non-T (B-) lineage and Tlineage. 18 Standard risk is defined as age from 1 to 9 years and a WBC of less than 50 000; high risk patients are all others, except for infants. In the second part of this section, major trial-specific findings are presented with updated longterm results.
Treatment results overall and in pre-defined subgroups by trial
In Table 1 , all four studies are listed with the median followup, the cumulative incidence of all events (early death, induction failure, death in CR, arelapse, and second malignancy), the cumulative incidence of any CNS-related or of isolated CNS-relapses, and the estimates for event-free and overall survival.
In study ALL-BFM 81, 98% of the 611 patients achieved complete remission (CR). 174 patients (30.3%) suffered from relapse (Table 1; Figure 2 ). The estimated probability of eventfree survival (pEFS) at 5 years, 8 years, and 10 years was 67.5 ± 2.0%, 65.8 ± 2.0%, and 63.5 ± 2.0%, respectively (Figure 2 ). The median follow-up of patients in CCR is 13.75 years (range 10.5-17.5 years). Estimate for overall survival was 80.6 ± 1.6% at 5 years, 77.6 ± 1.8% at 8 years, and 76.0 ± 1.8% at 10 years. The cumulative incidence of any relapse with CNS involvement was 9.6 ± 1.4% (isolated 5.1 ± 1.0%) at 5 years, and 10.1 ± 1.4% (isolated 5.3 ± 1.1%) at 8 and at 10 years (Table 1, Figure 2 ). The immunophenotype was available in 517 patients. According to NCI criteria, standard risk (SR) patients with non-T lineage fared better than high risk (HR) patients (Table 2, Figure 3a ). The outcome in SR patients (according to the BFM definition) was slightly better than the outcome of MR patients (P = 0.05, log-rank) but significantly better than in HR (P = 0.0001, log-rank) ( Table 2) . MR patients did significantly better than HR patients (P = 0.01). 17 of 215 events occurred more than 8 years from diagnosis. Among these, nine were late relapses, seven were
Figure 2
Probability of event-free survival (pEFS) in the four consecutive studies ALL-BFM 81, 83, 86, and 90 (s.e. = standard error) as listed per study. Lower curves indicate the cumulative incidence (CI) of all relapses with CNS involvement in these four trials, numbers are provided for the CI of CNS relapses at 8 years. For differences in pEFS or cumulative incidence of CNS relapses, see text.
second malignancies, and one patient died without prior relapse or second malignancy.
Six hundred and forty-one (98.1%) of the 653 patients in study ALL-BFM 83 achieved CR, 216 patients (34.6%) relapsed (Tables 1 and 3 ). The median follow-up of patients in CCR is 11.06 years (range 8.0-16.1 years) 5 years pEFS for all patients was 64.3 ± 1.9%, and 10 years pEFS was 61.6 ± 2.0% (Table 1, Figure 2) ; the estimate for overall survival at 5 years was 76.1 ± 1.7 and 70.9 ± 1.9% at 10 years. The cumulative incidence for any CNS relapse was 9.3 ± 1.4% (isolated CNS relapse 2.7 ± 0.7%) at 8 and 10 years (Table 1, Figure 2) . Best subsets are patients with hyperdiploidy (10 years pEFS 75.1 ± 5.3%), WBC Ͻ10 000 (10 years pEFS 66.6 ± 2.8%), patients 1-9 years of age (10 years pEFS 65.9 ± 2.2%), and female patients (10 years pEFS 65.0 ± 2.9%). In 613 (94%) of the 653 patients, the centralized evaluation of the peripheral blood response to prednisone was successful: 8% of the patients had у1000 blasts per l (PRED poor response). Their 8 years pEFS is 37.6 ± 7.0%, as compared to 64.6 ± 2.1% for patients with PRED good response (log rank, P = 0.0001). The analysis by the NCI risk criteria (see above) revealed that B-lineage patients with SR characteristics did better than those with HR criteria (Table 3, Figure 3b ): P = 0.0001, log-rank. Analyzing patients by immunophenotype, 10 years pEFS of B-lineage patients (62.3 ± 2.2%) was significantly better than that of T-lineage patients (52.7 ± 5.5%) (P = 0.004). When analyzed according to the BFM risk groups, SR-L, SR-H, and MR patients did significantly better than HR patients (SR-L vs HR, P = 0.0003; SR-H vs HR P = 0.0045, MR vs HR, P = 0.01). Six out of 242 events occurred more than 8 years from diagnosis (three relapses, two secondary malignancies, and one death unrelated to disease).
98.5% of the 998 patients of trial ALL-BFM 86 attained complete remission, 255 patients (26.8%) relapsed, and 1.5% died in CR. The treatment intensifications such as increase of anthracycline dose, introduction of high-dose MTX, the use of protocol E for HR patients, and the use of the more intensive reinduction (protocol II) for all patients (in SRG only after protocol amendment) did not increase the cumulative risk of fatal complications (Table 1) . Five years pEFS was 72.1 ± 1.4%, 8 years pEFS was 70.4 ± 1.5%, and 10 years pEFS was 69.0 ± 1.5% (Table 4, Figure 2 ). The overall survival estimate at 10 years was 77.9 ± 1.4%. The median follow-up time of patients in CCR is 9.43 years (range 3.9-13.4 years). With regard to the BFM risk groups, high risk patients (EG) did significantly worse than SRG and MRG patients. No difference was found between standard and medium risk patients having achieved a 10 years pEFS of 70.6 ± 3.0% and 72.1 ± 1.9%, respectively (Table 4) . A large difference, however, was found between SRG patients treated without reintensification (protocol II) and SRG patients treated with reintensification: 8 years pEFS was 83.6 ± 3.0% if protocol II had been used, but only 55.3 ± 4.9% if protocol II had been omitted (P = 0.0001, log-rank). Using WBC for subdividing the patients, 80% (all patients with Ͻ50 000 WBC, including infants) had a 10 years pEFS above 70%. Using the prednisone response, 90% could be defined with an 8 years pEFS of above 70%. Best subsets were female patients (8 years pEFS 75%), patients with DI 1.16-1.60 (8 years pEFS 86%), NCI-SR for non-T lineage (8 years pEFS 77%), and NCI-SR for T-lineage (8 years pEFS 92%). Both NCI-SR subsets did significantly better than the corresponding NCI-HR subsets (log-rank for T-lineage: P = 0.0063; for B-lineage: P = 0.0001) (Figure 3c ). The worst subsets (with a 8 years pEFS below 50%) were infants (8 years pEFS 36%), patients with Ph + ALL (8 years pEFS 14%), and patients with PRED-PR (8 years pEFS 46%). Control of CNS recurrences is shown by Figure 2 . The cumulative incidence of CNS relapses in trial ALL-BFM 86 at 5 years was 5.0 ± 0.8% (isolated CNS relapse 1.8 ± 0.5%), and at 8 and 10 years Leukemia 5.1 ± 0.8% (isolated CNS 1.9 ± 0.5%). Outcome of patients with initial CNS involvement (8 years pEFS 66.7 ± 8.6%) was not significantly worse than that of CNS negative patients (8 years pEFS 70.8 ± 1.5%; P = 0.60). There was also no difference in outcome for patients with B-lineage and T-lineage ALL (log-rank, P = 0.81). In study ALL-BFM 86, 10 patients had an event (out of 298 events) more than 8 years from diagnosis (seven relapses, and three secondary malignancies).
In study ALL-BFM 90, 98.3% of 2178 patients attained CR; 35 (1.6%) died in CR, and 409 patients relapsed (20.1%, see Table 1 ). The median follow-up time is 6.04 years (0.1-9.8 years). Five years pEFS was 78 ± 0.9%, and 8 years pEFS was 75.9 ± 1.0% (Tables 1, 5 , and Figure 2 ). The overall survival estimate at 8 years was 83.5 ± 0.9%. The cumulative incidence of CNS relapses at 5 years was 3.1 ± 0.4% (for isolated CNS relapse 1.1 ± 0.2%), and at 8 years was 3.2 ± 0.4% (for isolated CNS relapse 1.1 ± 0.2%) (Table 1, Figure 2 ). According to NCI risk criteria, a large difference was found with regard to outcome in non-T lineage patients (Figure 3d ): SR non-T lineage patients had an 8 years pEFS of 84.9 ± 1.1% as compared to 64.2 ± 2.3% in HR patients (P = 0.0001, logrank). The results in T-lineage patients were also significantly different: HR patients had an 8 years pEFS of 57.0 ± 3.5% vs 69.0 ± 5.9% in SR patients (P = 0.03) (Figure 3d) . Overall, all B-lineage patients achieved an 8 years pEFS of 78.1%, and Tlineage patients of 60.2 ± 3.0% (P = 0.0001). For several patient characteristics an improved 8 years pEFS of у80% as compared to previous studies was found: non-T NCI-SR, Table 3 Long-term result of study ALL-BFM 83 (1983 Figure 2 ) in the estimate of pEFS by the log-rank test, no difference was found between study ALL-BFM 81 and study ALL-BFM 83 (P = 0.37). Study ALL-BFM 90 fared better in pEFS than all other studies (P value in all comparisons Ͻ0.005), and ALL-BFM 86 had a better outcome than ALL-BFM 83 (P = 0.0019) and ALL-BFM 81 (P = 0.05). With regard to overall survival, a significantly better outcome was found for ALL-BFM 81 vs Leukemia ALL-BFM 83 (P = 0.04), and for all comparisons of study ALL-BFM 90 vs other studies (P values Ͻ0.01). The survival estimate was not different between studies ALL-BFM 81 and 86 (P = 0.48). The analysis of cumulative risk of relapses with CNS involvement reveals a significantly lower risk in study ALL-BFM 90 as compared to all other studies (P value (Gray's test) Ͻ0.01 in all comparisons). Even though the CI of CNS relapses was higher in study ALL-BFM 86 than in study ALL-BFM 90 (P = 0.0099), it was significantly lower in study 86 than in studies ALL-BFM 81 (P = 0.00025) and 83 (P = 0.0015).
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Figure 3
Long-term results of four consecutive trials in childhood ALL
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Treatment results derived from study questions Treatment duration:
In studies ALL-BFM 81 and 83, 764 patients were randomized to evaluate the impact of 6 months Table 4 Long-term result of study ALL-BFM 86 (1986 of maintenance therapy (18 vs 24 months; Figure 1 ). Previously, an advantage for the longer therapy duration was reported. 9, 32 This updated evaluation demonstrates at 8 years an estimated disease-free survival (p-DFS) at 77.3 ± 2.3% for patients randomized for 24 months (n = 375), and at 71.2 ± 2.4% for patients randomized for 18 months (n = 389) (Figure 4) . The log-rank test (P = 0.11) does not reveal a significant difference due to the late events occurring more than 10 years from diagnosis. The same result is found if the outcome is analyzed for each trial separately. If the cumulative incidence of CNS related and other events are calculated at 10 years from randomization, no difference for CNS recurrences (P = 0.8) but a trend for difference for other relapses is found being in favor of 24 months (P = 0.07). Also, if the test for a difference of the Kaplan-Meier estimates at 10 years is applied, a significant difference in favor of 24 months is found (P = 0.025).
Presymptomatic CNS treatment:
In study ALL-BFM 81, 59.2% of the total patient population belonged to the standard risk group defined by the BFM risk factor (RF Ͻ1.2). Within this subgroup, the replacement of CRT (18 Gy in arm SR-A, Figure 1 ) by intermediate-dose (IDM) MTX (arm SR-B) was evaluated in a randomized study with 277 patients (Figure 5a ). The number of IT MTX applications was seven in both arms. In the log-rank test, no significant difference could be found (P = 0.13) even though a large difference in the cumulative incidence of CNS relapses was noted (P = 0.0006, Gray's test). Only when the subset of patients with a higher risk factor (high-standard risk, RF 0.8-Ͻ1.2; n = 153) were analyzed, could a difference be found which was significant for CNS recurrences (P = 0.0005, Gray's test) but not for other events: a 4.5-fold lower incidence of combined and a 8.6-fold lower incidence of isolated CNS relapses (at 10 years) was found in patients treated with cranial irradiation. Table 5 Long-term result of study ALL-BFM 90 (1990 In study ALL-BFM 83, the group of high-standard risk patients (SR-H) were treated with IDM MTX in consolidation, and with CRT after reintensification (Figure 1) . A randomized study with 143 patients comparing 12 Gy and 18 Gy found no effect of the radiation dose on p-DFS or cumulative incidence of CNS relapses (Figure 1 and 5b) . The cumulative incidence of CNS relapses in SR-H is nearly identical when compared to the corresponding subset of high-standard risk patients (RF 0.8-Ͻ1.2) of study ALL-BFM 81 in arm SR-A (with 18 Gy CRT) indicating that the introduction of IDM MTX either had no benefit or was outbalanced by the less effective induction therapy of study ALL-BFM 83.
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Reintensification:
In study ALL-BFM 83, 126 patients in the low-standard risk group (BFM-RF 0.8, and absence of mediastinal mass or CNS disease) were randomized to receive or not receive reintensification with protocol III after interim maintenance with IDM MTX (Figure 1 ). Patients did not receive CRT. As shown in Figure 6a , patients receiving protocol III had a major benefit (P = 0.0016) which was mainly due to the lower incidence of systemic recurrences in arm SR-l/2 (with protocol III). Patients receiving reintensification had a cumulative incidence of CNS recurrences which was slightly lower than in patients treated without reinduction (P = 0.07, Gray's test).
In study ALL-BFM 86, a very similar observation was made in a non-randomized comparison of standard risk patients (defined by BFM-RF Ͻ0.8 and the absence of mediastinal or CNS involvement as in study ALL-BFM 83, but also by PGR) treated in the first part of trial ALL-BFM 86 without reinduction with patients treated with reinduction (by protocol II) after amendment of the protocol (Figure 1 ). Despite the use of HD-MTX during consolidation in that study, reinduction with protocol II had a major impact on the number of relapses (Figure 6b ). The difference in relapse incidence between both patient groups was due to systemic relapses, and not due to the number of CNS relapses.
Early in vivo response to prednisone:
In studies ALL-BFM 83, 86, and 90, the in vivo response of the leukemic clone to prednisone as measured in peripheral blood was analyzed in 3735 patients (Figure 7a, b and c) . Since 1986, the prednisone response has been used for stratification of patients. Figure 2 ) has been achieved by improvement of disease control among patients with PGR: 8 years pEFS is 64.6% in study ALL-BFM 83, 73.2% in study ALL-BFM 86, and 80.7% in study ALL-BFM 90.
Discussion
The results achieved in four large multicenter trials of the ALL-BFM study group from 1981 to 1995 indicate that a 75% longterm event-free survival is possible with contemporary treatment. Fortunately, the largest improvement in the last four BFM trials was made among B-lineage patients which is the largest subgroup (Tables 2-5 ). Among B-lineage patients, NCI standard risk patients which comprise 60% of all patients have achieved an 8 year pEFS of 84.9 ± 1.1% in the most recent study ALL-BFM 90. Interestingly, two studies (ALL-BFM 81 and 86; Tables 2 and 4) provided a similarly favorable outcome for NCI-SR patients with T cell ALL which was close to that reported for T cell lymphoblastic non-Hodgkin lymphoma. 12 The favorable outcome of T cell leukemia patients in those two studies cannot fully be explained. In study ALL-BFM 81, a very intensive L-ASP schedule was used in induction, thus providing a high dose intensity in protocol I. In study ALL-BFM 86, one beneficial factor for the subset of T cell ALL might have been the use of an increased anthracycline dose in induction.
This analysis raises the question of how quality of treatment
Figure 4
Evaluation of treatment duration in studies ALL-BFM 81 and 83. Probability of disease-free survival (pDFS) from time of randomization (at 18 months from diagnosis) for patients from trials ALL-BFM 81 and 83 randomized for treatment duration. Log-rank P = 0.11. Lower curves indicate the cumulative incidence of all relapses with CNS involvement according to treatment duration.
should be assessed, and what the endpoints of such an analysis should be. Previously, the prevention of recurrence was the major target for therapeutic intervention. 27, 33 Without any doubt, systemic relapses remain the main obstacle of cure (Table 1) . Figures 1 and 2 indicate that treatment adaptations such as the introduction of high-dose methotrexate and the intensified early use of IT MTX can improve control of extramedullary relapses despite elimination or reduction of presymptomatic radiotherapy. 13, 34, 35 Events other than relapse, even though being quite rare, need specific attention, in particular fatal events in CR and second malignancies (Table 1) . Fatalities in CR reflect the acute toxicity of treatment and the experience of the clinical staff. The BFM results in that regard are similar to those of other study groups. [36] [37] [38] [39] [40] [41] [42] The question as to whether or not acute and chronic toxicities are in adequate balance to treatment outcome is hard to assess. Direct comparisons of treatment programs can be very useful to that end. 43, 44 The contribution of cranial radiotherapy to the development of second malignancies is evident in the BFM trials as recently shown. 45 In the most recent trial ALL-BFM 95, CRT was limited to high-risk ALL and T-lineage (combined, approximately 20% of all patients).
The overall result of study ALL-BFM 83 and the result in low-standard risk patients (SR-L) of that study indicate that reduction of treatment burden (reduction of dose intensity in induction; elimination of reintensification) can have a major adverse impact on outcome (Figures 2 and 6a) . In particular, the finding that delayed reinduction is an essential element for systemic disease control, even among low/standard risk patients, illustrates that the relevance of any given prognostic factor is dependent on adequate treatment (Figure 6b) . 11, 38 In study ALL-BFM 76, the negative impact of high WBC at diagnosis was at least partly diminished by the introduction of reintensification (protocol II) for high-risk patients. It appeared that the delayed use of reintensification was more effective and less toxic than the early use. 5, 6 At the same time, the impact of late intensification using a different design was found not to be of benefit by investigators from St Jude. 46 For high-risk patients mainly characterized by prednisone poor response in trial ALL-BFM 90, a shorter induction phase and a reinforced consolidation with short intensive pulses was introduced to prevent the early relapses which are typical for these patients (Figure 1) . 10, 11 The poor prognosis of that small subset could not be improved despite dose intensification with L-ASP, DEXA, 6-TG, Ara-C, MTX, and the introduction of VP-16. Most likely, the reduction of alkylating agents as compared to the previous high risk regimen had an adverse impact. 13 A CCG study with reinforced and more continuous exposure to cytotoxic drugs improved outcome for high-risk patients. 47 The results of the four trials presented here indicate that stepwise reduction of CRT is possible (Figures 2, 5a and b) . The first attempts, however, had failed due to a lack of efficacy of IDM MTX (0.5 g/m 2 ) in preventing CNS recurrences in study ALL-BFM 81. In particular, when patients from the highstandard risk group (BFM risk factor 0.8-Ͻ1.2) were analyzed in study ALL-BFM 81, a significantly lower incidence of CNS relapses was found in patients treated with cranial irradiation. 48 In male patients, however, IDM MTX given in the consolidation phase was significantly more effective in preventing testicular relapses than the low-dose MTX (20 mg/m 2 /week × 8, p.o.) applied in arm SR-A. 49 After 12 Gy of CRT had been found as effective as 18 Gy for high-standard risk (SR-H) patients in study ALL-BFM 83, and after having reduced CRT in study ALL-BFM 86 without an increase of CNS-related relapses, the CNS-directed radiotherapy could be further reduced in study ALL-BFM 90. The cumulative incidence of any CNS relapses at 5 years dropped to 3.1 ± 0.4% in study ALL-BFM 90. This is remarkably low considering the fact that 29.2% of patients (all SRG patients) did not receive CRT, and the rest of the CNS-negative patients were treated with only 12 Gy of radiotherapy (if age was Ͼ1 year at time of CRT), and a total of 11 IT MTX injections during the intensive phases of treatment. IT MTX and VCR/steroid pulses were not used in maintenance therapy as in other trials. 38 ,40,41 The cumulative incidence rates for CNS relapses in studies ALL- BFM 86 and 90 in which high-dose MTX has been used were significantly lower (P value in all comparisons Ͻ0.005, Gray's test) as in studies ALL-BFM 81 and 83 (using CRT and/or IDM-MTX) (Table 1, Figure 2) .
The in vivo response to treatment has been established as one of the strongest prognostic factors. The morphological evaluation of blood smears yields highly reproducible results, whereas the evaluation of bone marrow smears is occasionally limited due to low cellularity or dilution. Both methods have certain limitations in terms of sensitivity. [50] [51] [52] Early response to treatment such as the prednisone response is the most important prognostic factor because it is likely to be the result of drug uptake and metabolism, expression of resistance genes, and maybe of immunological factors. 10, [53] [54] [55] [56] [57] [58] [59] Even among patients with very unfavorable features such as infants or patients with a high risk genetic marker such as the PhilaLeukemia delphia chromosome, the in vivo response evaluation reveals a large heterogeneity in seemingly homogenous subgroups. 11, 13, [60] [61] [62] [63] The development of more sensitive detection techniques of residual leukemia has been an important contribution to diagnostics during follow-up. [64] [65] [66] [67] Clonospecific identification of residual leukemia was prospectively evaluated during trial ALL-BFM 90 in representative subsets of patients within a study of the International BFM Study Group (I-BFM-SG). 68 This study as others, emphasized the capability of response evaluation with such sensitive technology for risk assessment in childhood ALL. 69, 70 Further progress in the treatment of childhood ALL can only be achieved by large, controlled randomized clinical trials, and in small high risk subgroups, by close collaboration of the laboratories and study centers involved in each trial in order to combine data. This has recently been proven successful for Evaluation of reintensification for standard risk ALL. (a) pDFS for patients with low-standard risk ALL (SR-L; BFM risk factor Ͻ0.8) from study ALL-BFM 83 randomized for treatment with or without reintensification (Protocol III). Log-rank P = 0.0016. The cumulative incidence of relapses with CNS involvement was slightly higher in SR-L/1 than in SR-L/2. (b) pDFS for patients with 'standard risk' ALL (SRG; BFM risk factor Ͻ0.8 and prednisone good response) from study ALL-BFM 86 treated without (before amendment of protocol) or with reintensification (Protocol II). Log-rank P = 0.0001. Lower curves indicate the cumulative incidence of all relapses with CNS involvement. patients with Ph + ALL. 71 Within the International BFM Study Group, the Dutch Childhood Leukemia Study Group, the Italian AIEOP group, the Belgian-French CLCG-EORTC study group, the Chilean PINDA, the Argentine GATLA group, the Czech Childhood Leukemia Working Group, and the Hungary ALL study group have previously shared treatment modules with the ALL-BFM study group in the context of new treatment strategies. [72] [73] [74] This common approach has more recently been applied to a large prospective randomized trial on reinforced maintenance therapy for intermediate risk patients with study groups from Europe and South America.
Figure 7
Evaluation of prednisone response in studies ALL-BFM 83, 86, and 90. (a) pEFS in trial ALL-BFM 83 according to prednisone response; log-rank, P = 0.0001. (b) pEFS in trial ALL-BFM 86 according to prednisone response; log-rank, P = 0.0001. (c) pEFS in trial ALL-BFM 90 according to prednisone response; log-rank, P = 0.0001. Lower curves indicate the cumulative incidence of any relapses with CNS involvement among patients with PRED good response. Significant differences in the cumulative incidence of CNS relapses were found between PGR and PPR patients only in studies ALL-BFM 83 and 86.
